Clinical Trial Search

Primary: Number of Participants With Any Adverse Event, Adverse Events With Severity, Adverse Events Leading to Discontinuation — 346; 115; 15; 7 participants

Primary: Progression-free Survival — 4.7; 5.1 months

Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment — 100.0; 66.0 percentage of participants — p=<0.001

Primary: Number of Participants With Reduction in the Observed Numbers of Basal Cell Carcinomas ≥ 9 mm² in Diameter — 5; 29 participants

Primary: Number of Subjects With Left Ventricular Recovery and LVAD Explant — 8 Participants

Primary: Percentage of Participants Achieving Sustained Virological Response (SVR) According to Cumulative Dose of Ribavirin — 54.29; 60.87; 53.13; 50.00 percentage of…

Primary: Mean Change From Baseline in Calculated Disease Activity Score Based on 28 Joint Count Erythrocyte Sedimentation Rate at Week 24 — -2.795; -1.945 Units on a scale…

Primary: Number of Subjects With Vaccine Response to Anti-gE Antibodies — 366 Subjects

Primary: Median Time to PSA Progression

Primary: Safety of Twice a Day Oral 150 mg Erlotinib Dosing — 9 participants

Primary: If Eribulin Mesylate, up to a Maximum Dose of 1.4 mg/m2 Day 1 and 8 of a 21 Day Cycle, Can be Safely Combined With Full Dose Cetuximab for Patients With Advanced Head…

Primary: Person-years of Follow-up of Tenofovir 1% Gel and Vaginal Placebo Gel Arms — 1024; 1030 person-years

Primary: Percentage of Participants With Serious Adverse Events (SAEs) and Adverse Events (AEs) — 44.28; 3.9 percentage of participants

Primary: Reduction in Proteinuria in Recurrent FSGS Following Renal Transplant With Plasma Exchange and Cyclophosphamide. — 0; 0; 0.5; 0.25 proportion of participants with…

Primary: Number of Participants Receiving Biological Agent as Monotherapy or in Combination With Conventional Synthesis Disease-modifying Anti-rheumatic Drugs (csDMARDs) Therapy…